The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 14, 2025

Filed:

Jan. 24, 2022
Applicants:

Massachusetts Institute of Technology, Cambridge, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Natalie Boehnke, Cambridge, MA (US);

Joelle Payne Straehla, Cambridge, MA (US);

Angela Koehler, Cambridge, MA (US);

Paula Hammond, Cambridge, MA (US);

Assignees:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/7105 (2006.01); A61K 9/127 (2006.01); A61K 9/16 (2006.01); A61K 38/46 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C12N 15/113 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7105 (2013.01); A61K 9/1271 (2013.01); A61K 9/1617 (2013.01); A61K 9/1635 (2013.01); A61K 9/1647 (2013.01); A61K 38/465 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12N 15/1135 (2013.01); C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); C12N 2320/34 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01);
Abstract

SLC46A3 has been identified as a lipid-based nanoparticle-specific biomarker predictive of nanoparticle-cancer cell affinity. SLC46A3 has a strong inverse association with lipid-based nanoparticle uptake across multiple nanoparticle formulations. Tissues with decreased expression levels of SLC46A3 have a greater uptake of lipid-based nanoparticles. The inverse relationship of SLC46A3 expression in tumor tissue and affinity for lipid-based nanoparticles has therapeutic and diagnostic implications, including cancer therapy and diagnosis, and identification of patients most likely to benefit from a lipid-based nanotherapeutic for improved stratification in clinical trials.


Find Patent Forward Citations

Loading…